News & Updates

Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.

Several factors, including older age, overnight emergency department (ED) arrival time, higher serum urate (SU), higher C-reactive protein (CRP), and higher total white cell count at presentation, predict hospitalization for acute gout, according to a study.

Smoking, extra-articular manifestations (EAMs), and comorbidities are all associated with a higher risk of all-cause mortality in hospitalized patients with ankylosing spondylitis (AS) than those in the comparison cohort, reports a study.

Isolated bronchiectasis (BR) in rheumatoid arthritis (RA) that is not caused by interstitial lung disease (ILD) is associated with seropositivity, older age at RA diagnosis, and lower body mass index (BMI) at RA onset, a recent study has found.

The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.

Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.

Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.

A distinct community and greater heterogeneity have been observed in the plasma microbiome compared to the gut in both patients with systemic lupus erythematosus (SLE) and healthy individuals, reports a recent study. This suggests that the predominant circulating microbiome may originate from sites other than the gastrointestinal tract.

Patients with gout who refuse to take allopurinol for their condition do so because of their desire to lead a normal life and to test whether they could reduce the dose without experiencing any symptoms, a recent study has found.